A phase i study of ixazomib and erlotinib in patients with advanced solid tumors

Conclusions.  The combination of erlotinib and ixazomib was safe and well tolerated among patients with advanced cancer, with preliminary signals of antitumor activity in patients with advanced sarcoma.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research